MedTrace Logo

Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma

NCT03668730 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 215

Last updated 2021-08-24

No results posted yet for this study

Summary

To study the 2-year PFS (progression-free survival) of patients with stage III nasopharyngeal carcinoma of pretreatment EBV DNA\<4000 copy/ml treated with induction chemotherapy followed by two different doses of intensity-modulated radiation therapy and cisplatin.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

RADIATION

Intensity-modulated radiation therapy

Patients undergo low-dose OR standard dose IMRT based on their radiographic response to induction chemotherapy

DRUG

Paclitaxel liposome

Patients receive Paclitaxel liposome by 135mg/m2 with a total of two cycles.

DRUG

Cisplatin

Patients receive Cisplatin by 25mg/m2 on day1-day3 with a total of two cycles as induction chemotherapy ; patients receive cisplatin by 100mg/m2 with a total of three cycles as concurrent chemotherapy.

DRUG

5-Fluorouracil

Patients receive 5-Fluorouracil by 3750mg/m2 civ120h with a total of three cycles.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Hai Qiang Mai, MD.PHD · Sun Yat-sen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-19
Primary Completion
2021-12-31
Completion
2023-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03668730 on ClinicalTrials.gov